Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib

J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e120-e121. doi: 10.1111/jdv.16850. Epub 2020 Sep 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Histiocytosis, Langerhans-Cell* / complications
  • Histiocytosis, Langerhans-Cell* / drug therapy
  • Histiocytosis, Langerhans-Cell* / genetics
  • Humans
  • Leukemia, Myelomonocytic, Chronic* / complications
  • Leukemia, Myelomonocytic, Chronic* / drug therapy
  • Leukemia, Myelomonocytic, Chronic* / genetics
  • Mutation
  • Proto-Oncogene Proteins B-raf / genetics
  • Vemurafenib / therapeutic use

Substances

  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf